Trial Outcomes & Findings for A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults (NCT NCT04839562)

NCT ID: NCT04839562

Last Updated: 2024-03-04

Results Overview

Difference between active and placebo for change in Adult ADHD Investigator Symptom Rating total score from baseline to week 6 visit. The minimum score on this scale is 0, the maximum score for the scale is 54 points.Higher numbers indicate more ADHD symptoms, lower scores reflect lower ADHD symptoms.

Recruitment status

COMPLETED

Study phase

PHASE2/PHASE3

Target enrollment

66 participants

Primary outcome timeframe

six weeks

Results posted on

2024-03-04

Participant Flow

66 participants signed consent to participate in the study, per definition of enrollment. 6 of these participants ended up being excluded, and were never exposed (3 lost to follow up, 2 withdrew, 1 found to be ineligible after enrollment). 60 participants total were exposed to solriamfetol or placebo.

Participant milestones

Participant milestones
Measure
Solriamfetol
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Overall Study
STARTED
29
31
Overall Study
COMPLETED
29
29
Overall Study
NOT COMPLETED
0
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Solriamfetol
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Overall Study
Withdrawal by Subject
0
1
Overall Study
Physician Decision
0
1

Baseline Characteristics

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=31 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Total
n=60 Participants
Total of all reporting groups
Age, Continuous
36.2 years
n=99 Participants
36.9 years
n=107 Participants
36.6 years
n=206 Participants
Sex/Gender, Customized
Male
10 Participants
n=99 Participants
17 Participants
n=107 Participants
27 Participants
n=206 Participants
Sex/Gender, Customized
Female
17 Participants
n=99 Participants
12 Participants
n=107 Participants
29 Participants
n=206 Participants
Sex/Gender, Customized
Other
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
4 Participants
n=99 Participants
2 Participants
n=107 Participants
6 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
25 Participants
n=99 Participants
29 Participants
n=107 Participants
54 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
3 Participants
n=99 Participants
2 Participants
n=107 Participants
5 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
5 Participants
n=99 Participants
2 Participants
n=107 Participants
7 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Race (NIH/OMB)
White
19 Participants
n=99 Participants
25 Participants
n=107 Participants
44 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Highest Education
High School Graduate
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Highest Education
Some college but no college degree
4 Participants
n=99 Participants
2 Participants
n=107 Participants
6 Participants
n=206 Participants
Highest Education
Associate's Degree
2 Participants
n=99 Participants
3 Participants
n=107 Participants
5 Participants
n=206 Participants
Highest Education
Bachelor's or RN Degree
10 Participants
n=99 Participants
16 Participants
n=107 Participants
26 Participants
n=206 Participants
Highest Education
Some graduate school but no graduate degree
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Highest Education
Master's Degree
3 Participants
n=99 Participants
2 Participants
n=107 Participants
5 Participants
n=206 Participants
Highest Education
Doctoral or Law Degree
7 Participants
n=99 Participants
6 Participants
n=107 Participants
13 Participants
n=206 Participants
Marital Status
Married
13 Participants
n=99 Participants
12 Participants
n=107 Participants
25 Participants
n=206 Participants
Marital Status
Unmarried
16 Participants
n=99 Participants
19 Participants
n=107 Participants
35 Participants
n=206 Participants
Socioeconomic Status
98349 Dollars
STANDARD_DEVIATION 31349 • n=99 Participants
119593 Dollars
STANDARD_DEVIATION 33612 • n=107 Participants
109325 Dollars
STANDARD_DEVIATION 34041 • n=206 Participants
Clinical Global Impressions Severity (Baseline)
4 Moderately Ill
22 Participants
n=99 Participants
25 Participants
n=107 Participants
47 Participants
n=206 Participants
Clinical Global Impressions Severity (Baseline)
5 Markedly Ill
7 Participants
n=99 Participants
6 Participants
n=107 Participants
13 Participants
n=206 Participants
Global Assessment of Functioning Scale Score (Baseline)
63.8 total score on a scale
n=99 Participants
63.8 total score on a scale
n=107 Participants
63.8 total score on a scale
n=206 Participants

PRIMARY outcome

Timeframe: six weeks

Difference between active and placebo for change in Adult ADHD Investigator Symptom Rating total score from baseline to week 6 visit. The minimum score on this scale is 0, the maximum score for the scale is 54 points.Higher numbers indicate more ADHD symptoms, lower scores reflect lower ADHD symptoms.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=31 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score
-7.6 score on a scale
Interval -9.9 to -5.3
-2.1 score on a scale
Interval -4.4 to 0.2

PRIMARY outcome

Timeframe: six weeks

25% reduction in ADHD symptoms as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), and a Clinical Global Impression Improvement score of 2 (much) or 1 (very much) improved. The minimum score on the AISRS scale is 0, the maximum score for the scale is 54 points.Higher numbers indicate more ADHD symptoms, lower scores reflect lower ADHD symptoms. The Clinical Global Impression (CGI) Improvement scores range from 0 to 7, with 0=not assessed,1=very much improved), 2=much improved, through to 7=very much worse. Lower scores therefore mean better outcomes.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=31 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
A Priori Definition of Clinical Improvement
13 Participants
2 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. Ther are 9 subscales that are indexed under two categories, Behavioral Regulation (BRI) and Metacognition (MI), and these indexes form the overall summary score, the Global Executive Composite (GEC). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Global Executive Composite Index
20 Participants
10 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores. The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales that are indexed under two categories, one of which is Behavioral Regulation (BRI). The raw score of the BRI is converted into a T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Behavioral Regulation Index
18 Participants
11 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales that are indexed under two categories, one of which is Metacognition Index (MI). The raw score of the MI is converted into a T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Metacognition Index
19 Participants
10 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Inhibit subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Inhibit Subscale
11 Participants
10 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. Ther are 9 subscales that are indexed under two categories, one of which is the Shift subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Shift Subscale
20 Participants
10 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Emotional Control subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Emotional Control Subscale
16 Participants
10 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Self-Monitor subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Self-Monitor Subscale
13 Participants
9 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Initiate subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Initiate Subscale
18 Participants
9 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores) The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Working Memory subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Working Memory Subscale
17 Participants
9 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Plan/Organize subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Plan/Organize Subscale
19 Participants
11 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Task Monitor subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Task Monitor Subscale
18 Participants
11 Participants

SECONDARY outcome

Timeframe: 6 weeks

We secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Organization of Materials subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.

Outcome measures

Outcome measures
Measure
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Organization of Materials Subscale
14 Participants
9 Participants

Adverse Events

Solriamfetol

Serious events: 0 serious events
Other events: 28 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 28 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Solriamfetol
n=29 participants at risk
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Solriamfetol 75 MG: Daily oral consumption Solriamfetol 150 MG: Daily oral consumption
Placebo
n=31 participants at risk
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated. Placebo: Placebo
Infections and infestations
Cold/Infection/Allergy
44.8%
13/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
54.8%
17/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Metabolism and nutrition disorders
Increased Appetite
0.00%
0/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Metabolism and nutrition disorders
Decreased Appetite
17.2%
5/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Headache
48.3%
14/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
29.0%
9/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Gastrointestinal disorders
Nausea/Vomiting/Diarrhea (Gastrointestinal)
24.1%
7/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Insomnia
31.0%
9/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
16.1%
5/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Sedation
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Increased Energy
13.8%
4/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Cardiac disorders
Cardiovascular
17.2%
5/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Tense/jittery
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
0.00%
0/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Agitated/irritable
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Psychiatric disorders
Anxious/Worried
0.00%
0/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Gastrointestinal disorders
Mucosal Dryness
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
12.9%
4/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Dizzy/Lightheaded
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
0.00%
0/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Nervous system disorders
Neurological
13.8%
4/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Musculoskeletal and connective tissue disorders
Musculoskeletal
24.1%
7/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
22.6%
7/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Renal and urinary disorders
Genitourinary
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
Skin and subcutaneous tissue disorders
Dermtological
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
12.9%
4/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
General disorders
Other
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
9.7%
3/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects

Additional Information

Dr. Craig Surman

Massachusetts General Hospital

Phone: 6176808489

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place